A common concurrent condition often appreciated in feline CKD patients is cardiac disease. High rate fluid therapy to treat azotemia puts these patients at risk for congestive heart failure (CHF). Anecdotally at Tufts, an improvement in azotemia, appetite and attitude has been noted in cats treated for cardiac disease with pimobendan that also have kidney disease. We would like to assess tolerability of pimobendan and possible benefits in patients with CKD, IRIS stage 3 or 4. Investigating these initial clinical observations with a larger study will help establish whether pimobendan could be a novel treatment for cats with kidney disease. Benefits could include decreased hospitalization time, improved appetite, improved kidney perfusion with reduced azotemia, and the ability to treat kidney disease while simultaneously protecting against CHF in patients with concurrent cardiac disease.
For more information regarding this study, please visit: http://sites.tufts.edu/vetclinicaltrials/specialty/internal-medicine/